Laboratory studies of one new treatment, the XTL-002 human monoclonal antibody, suggest it can reduce viral load in hepatitis C infection, developers XTL Biopharmaceuticals reported.
XTL, of Rehovot, Israel, reported on tests of the new drug on human liver fragments at the International Meeting on Hepatitis C and Related Viruses at Gold Coast, Queensland, Australia.
The company also reported promising results of a trial of another antibody, XTL-001. This involved 12 patients with chronic hepatitis B infection.
Preliminary results showed a "rapid and consistent" fall in signs of viral infection, researchers said, with HBV DNA measurements dropping to 0.001 per cent of their original levels.
There were no serious adverse events during the trial.
XTL president, Dr Martin Becker, said, "We are very optimistic about recent results from our HBV and HCV programs. Human monoclonal antibodies could have great potential as therapies for both HBV and HCV.
"We look forward to continuing our success and plan to begin trials of XTL-001 as combination therapy with lamivudine, the current standard treatment for HBV, as well as initiating human trials with our HCV antibodies in 2001."
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com